5,8-DihydroxypsoralenCAS# 14348-23-3 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 14348-23-3 | SDF | Download SDF |
PubChem ID | 5376215 | Appearance | Powder |
Formula | C11H6O5 | M.Wt | 218 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | 4,9-dihydroxyfuro[3,2-g]chromen-7-one | ||
SMILES | C1=CC(=O)OC2=C1C(=C3C=COC3=C2O)O | ||
Standard InChIKey | DZEPISXWRUMGFN-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C11H6O5/c12-7-2-1-5-8(13)6-3-4-15-10(6)9(14)11(5)16-7/h1-4,13-14H | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
5,8-Dihydroxypsoralen Dilution Calculator
5,8-Dihydroxypsoralen Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 4.5872 mL | 22.9358 mL | 45.8716 mL | 91.7431 mL | 114.6789 mL |
5 mM | 0.9174 mL | 4.5872 mL | 9.1743 mL | 18.3486 mL | 22.9358 mL |
10 mM | 0.4587 mL | 2.2936 mL | 4.5872 mL | 9.1743 mL | 11.4679 mL |
50 mM | 0.0917 mL | 0.4587 mL | 0.9174 mL | 1.8349 mL | 2.2936 mL |
100 mM | 0.0459 mL | 0.2294 mL | 0.4587 mL | 0.9174 mL | 1.1468 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Cnidilin
Catalog No.:BCN2731
CAS No.:14348-22-2
- Poriol
Catalog No.:BCN6816
CAS No.:14348-16-4
- (Arg)9 peptide
Catalog No.:BCC5336
CAS No.:143413-47-2
- SAR131675
Catalog No.:BCC5097
CAS No.:1433953-83-3
- Naratriptan
Catalog No.:BCC5053
CAS No.:143388-64-1
- Bryostatin 3
Catalog No.:BCC5620
CAS No.:143370-84-7
- SMIP004
Catalog No.:BCC1955
CAS No.:143360-00-3
- RS 56812 hydrochloride
Catalog No.:BCC6877
CAS No.:143339-12-2
- UNC 2400
Catalog No.:BCC5625
CAS No.:1433200-49-7
- Ac-YVAD-CHO
Catalog No.:BCC4021
CAS No.:143313-51-3
- H-Chg-OH
Catalog No.:BCC3162
CAS No.:14328-51-9
- RA-XI
Catalog No.:BCN3514
CAS No.:143277-27-4
- LOE 908 hydrochloride
Catalog No.:BCC7327
CAS No.:143482-60-4
- Emtricitabine
Catalog No.:BCC3774
CAS No.:143491-57-0
- Dammarenediol II
Catalog No.:BCN6240
CAS No.:14351-29-2
- 3-Acetoxy-24-hydroxydammara-20,25-diene
Catalog No.:BCN1569
CAS No.:143519-04-4
- (4S,5R)-3-(tert-Butoxycarbonyl)-2,2-dimethyl-4-phenyloxazolidine-5-carboxylic acid
Catalog No.:BCN8364
CAS No.:143527-70-2
- Shancigusin I
Catalog No.:BCN8272
CAS No.:1435488-35-9
- XMD17-109
Catalog No.:BCC2061
CAS No.:1435488-37-1
- L 012 sodium salt
Catalog No.:BCC6362
CAS No.:143556-24-5
- Rocuronium
Catalog No.:BCC1906
CAS No.:143558-00-3
- Virgatic acid
Catalog No.:BCN6744
CAS No.:14356-51-5
- Diprenorphine
Catalog No.:BCC5954
CAS No.:14357-78-9
- H-DL-Asp(OMe)-OMe.HCl
Catalog No.:BCC2901
CAS No.:14358-33-9
Disposition of 8-methoxypsoralen in the rat: methodology for measurement, dose-dependent pharmacokinetics, tissue distribution and identification of metabolites.[Pubmed:3944766]
J Pharmacol Exp Ther. 1986 Feb;236(2):364-73.
The pharmacokinetics and metabolism of 8-methoxypsoralen (8-MOP) were measured in the catheterized rat after a single i.v. dose. Blood samples were collected serially and analyzed using a sensitive and specific assay for [14C]-8-MOP. Total body clearance of 8-MOP was 7.3, 3.9, 1.7, 1.0, 0.78 and 0.42 liters/kg/hr at doses of 0.2, 1.0, 2.5, 5.0, 10 and 20 mg/kg, respectively. The decline in total body clearance indicates that elimination of 8-MOP is dose-dependent in the rat. After i.v. administration of 10 mg/kg of 8-MOP, 71 and 26% of the dose was recovered within 72 hr in the urine and feces, respectively. Unchanged 8-MOP accounted for less than 1% of the excreted radioactivity. In tissue distribution studies at 0.5, 2 and 5 hr after i.v. administration, 8-MOP distributed rapidly to all tissues and concentrated in the fat and kidneys. The concentration of 8-MOP in the skin was 0.4 to 0.6 times that in the blood. Eleven metabolites of 8-MOP were detected in the urine. The metabolites identified after enzymatic hydrolysis were 8-hydroxypsoralen; 5-hydroxy-8-methoxypsoralen; 5,8-Dihydroxypsoralen; 5,8-dioxopsoralen; 6-(7-hydroxy-8-methoxycoumaryl)-acetic acid and 8-MOP (formed by ring closure of a coumaric acid metabolite). Thus, these studies indicate that 8-MOP is metabolized in the rat by 1) O-demethylation; 2) hydroxylation at position 5; 3) hydrolysis of the lactone ring and 4) oxidation of the furan ring, a pathway already confirmed in insects, dogs and humans.
Disposition of 8-methoxypsoralen in the rat. Induction of metabolism in vivo and in vitro and identification of urinary metabolites by thermospray mass spectrometry.[Pubmed:2886306]
Drug Metab Dispos. 1987 May-Jun;15(3):318-28.
The pharmacokinetics and metabolism of 8-methoxypsoralen (8-MOP) were measured in the catheterized rat after pretreatment for 3 days with phenobarbital (PB), beta-naphthoflavone (BNF), 8-MOP, or vehicle. After an iv injection of 10 mg/kg of [14C]8-MOP, timed blood samples were collected and analyzed using a sensitive and specific assay for [14C]8-MOP. Total body clearance of 8-MOP increased from 0.55 +/- 0.06 liter/kg/hr in control rats to 5.6 +/- 0.4, 2.7 +/- 0.4, and 1.2 +/- 0.0 liters/kg/hr in rats pretreated with BNF, PB, and 8-MOP, respectively, indicating that all three compounds are inducers of 8-MOP metabolism. The pattern of urinary metabolites was altered by the enzyme inducers. The urinary excretion of the sulfate conjugate of 5-hydroxy-8-methoxypsoralen was increased from 10 to 40% of the dose after pretreatment with PB. This intact conjugate was identified using thermospray and fast atom bombardment mass spectrometry. Pretreatment with 8-MOP and BNF increased 2- and 3-fold, respectively, the urinary excretion of a labile sulfate conjugate of 5,8-Dihydroxypsoralen. Metabolism of 8-MOP was demonstrated in the 9000 g supernatant and microsomes of rat liver and shown to be inducible by pretreatment of rats with BNF, PB, and 8-MOP. 8-MOP was metabolized in incubations with liver microsomes at rates of 0.22 +/- 0.06, 0.38 +/- 0.06, 0.78 +/- 0.07, and 0.91 +/- 0.03 nmol/min/mg of protein for vehicle, 8-MOP-, PB-, and BNF-pretreated rats, respectively. Results of our investigation indicate that the success of therapy with 8-MOP may be influenced by pharmacokinetic interactions with other drugs.
Fate of [(14)C]xanthotoxin (8-methoxypsoralen) in laying hens and a lactating goat.[Pubmed:24254913]
J Chem Ecol. 1992 Feb;18(2):253-70.
The metabolism of xanthotoxin, a naturally occurring furanocoumarin photosensitizer, was studied in laying hens and a lactating goat treated with single oral doses equivalent to 10 mg xanthotoxin/kg of body weight. Within 48 h, essentially all of the administered radiocarbon was eliminated in the excreta of the laying hens, while in the goat 92% and 3% were excreted in the urine and feces, respectively. Radiocarbon residues in the milk, egg white, and egg yolk were low. Xanthotoxin, 8-hydroxypsoralen (xanthotoxol), 6-(7-hydroxy-8-methoxycoumaryl)-acetic acid (HCA) and 6-(7-hydroxy-8-methoxycoumaryl)-hydroxyacetic acid (HCHA) were identified in the excreta of laying hens. In the goat, xanthotoxin was metabolized to HCA, HCHA, xanthotoxol, 5,8-Dihydroxypsoralen, psoralenquinone, 5-hydroxy-8-methoxy-psoralen and 3[5-(6-hydroxy-7-methoxybenzofuryl)]-propanoic acid. Thus, identified metabolites in one or both of these species arose throughO-demethylation, oxidative cleavage of the furan ring, hydroxylation, reduction, oxidation, and hydrolysis of the lactone ring.